Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Brilinta Tablets 60mg/90mg Clinical Experience Investigation

NCT03212287 is registered in ClinicalTrials.gov with AstraZeneca as lead sponsor.

NCT NCT03212287
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT03212287 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Brilinta Tablets 60mg/90mg Clinical Experience Investigation
Lead sponsor
AstraZeneca
Phase
Observational
Overall status
Completed
Start date
December 21, 2017
Completion date
July 31, 2024
Enrollment
663 (actual)
Sites
71

Conditions

As the registry lists them; a condition with its own page is linked.

acute coronary syndrome, old myocardial infarction